Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 3 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions essential for maintenance of cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose 5% supplies calories and may reduce protein and nitrogen losses. Sodium chloride 0.3% supplies sodium and chloride ions to maintain electrolyte balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: 10-20 mEq/hour, not exceeding 30 mEq/hour or 200 mEq/24 hours; rate depends on severity of hypokalemia and patient tolerance.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable as potassium is an electrolyte regulated by renal function; in normal renal function, steady state achieved within 24-48 hours of continuous infusion
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% as potassium ions; minimal biliary/fecal (<5%)
Category C
Category A/B
Electrolyte
Electrolyte